Zhitong Finance App News, Xiansheng Pharmaceutical (02096.HK) announced that SIM0725, an antibody targeting CD122 developed independently by the Group, has obtained a drug clinical trial approval notice issued by the China National Drug Administration and is intended to be used to treat autoimmune diseases.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.